0	Isolation	<ROOT>	-1
1	and	Isolation	0
2	characterization	and	1
3	of	characterization	2
4	a	fucoganglioside	6
5	novel	fucoganglioside	6
6	fucoganglioside	of	3
7	of	fucoganglioside	6
8	human	membranes	10
9	erythrocyte	membranes	10
10	membranes	of	7
11	.	Isolation	0

0	Diverticulum	<ROOT>	-1
1	of	Diverticulum	0
2	the	calix	3
3	calix	of	1
4	in	Diverticulum	0
5	children	in	4
6	.	Diverticulum	0

0	General	anesthesia	1
1	anesthesia	<ROOT>	-1
2	and	anesthesia	1
3	long	term	4
4	term	and	2
5	psychotropic	treatments	6
6	treatments	term	4
7	.	anesthesia	1

0	Four	nitrosoureas	2
1	steroidal	nitrosoureas	2
2	nitrosoureas	were	13
3	with	nitrosoureas	2
4	structures	with	3
5	which	may	6
6	may	structures	4
7	permit	may	6
8	specific	binding	9
9	binding	permit	7
10	to	binding	9
11	estrogen	receptor	12
12	receptor	to	10
13	were	<ROOT>	-1
14	synthesized	were	13
15	.	were	13

0	Inhibitory	activity	1
1	activity	was	2
2	was	<ROOT>	-1
3	observed	was	2
4	against	was	2
5	the	growth	6
6	growth	mammary	12
7	of	growth	6
8	the	rat	11
9	DMBA-induced	rat	11
10	transplantable	rat	11
11	rat	of	7
12	mammary	against	4
13	tumor	13762	14
14	13762	mammary	12
15	.	was	2

0	Electrophoretic	differences	1
1	differences	<ROOT>	-1
2	in	differences	1
3	the	proteins	4
4	proteins	in	2
5	of	proteins	4
6	the	species	7
7	species	of	5
8	Pseudomonas	aeruginosa	9
9	aeruginosa	differences	1
10	and	aeruginosa	9
11	Pseudomonas	denitrificans	12
12	denitrificans	and	10
13	capable	denitrificans	12
14	of	capable	13
15	oxidizing	n-alkanes	16
16	n-alkanes	of	14
17	.	differences	1

0	Ultrahistochemical	study	1
1	study	<ROOT>	-1
2	of	study	1
3	the	effect	4
4	effect	of	2
5	of	effect	4
6	glucagon	of	5
7	and	glucagon	6
8	Chelaton	and	7
9	III	Chelaton	8
10	on	effect	4
11	arterial	structure	13
12	wall	structure	13
13	structure	on	10
14	after	study	1
15	experimental	calcification	16
16	calcification	after	14
17	.	study	1

0	Limitations	<ROOT>	-1
1	of	Limitations	0
2	aeruginocine	typing	3
3	typing	of	1
4	of	typing	3
5	PS.	aeruginosa	6
6	aeruginosa	of	4
7	as	Limitations	0
8	an	marker	10
9	epidemiological	marker	10
10	marker	as	7
11	.	Limitations	0

0	Effect	<ROOT>	-1
1	of	Effect	0
2	organic	mercurials	3
3	mercurials	of	1
4	and	Effect	0
5	sulfhydryl	compounds	6
6	compounds	and	4
7	on	compounds	6
8	the	activity	10
9	urease	activity	10
10	activity	on	7
11	of	activity	10
12	Proteus:	inhibition	13
13	inhibition	of	11
14	by	inhibition	13
15	urine	by	14
16	and	urine	15
17	ascorbic	acid	18
18	acid	and	16
19	.	Effect	0

0	The	care	4
1	annex	care	4
2	hospital--long	care	4
3	term	care	4
4	care	<ROOT>	-1
5	in	care	4
6	a	model	8
7	Stockholm	model	8
8	model	in	5
9	.	care	4

0	New	materials	1
1	materials	<ROOT>	-1
2	for	materials	1
3	painless	system	5
4	restoration--GK-101	system	5
5	system	for	2
6	.	materials	1

0	Experience	<ROOT>	-1
1	in	Experience	0
2	using	in	1
3	P.	hamadryas	4
4	hamadryas	using	2
5	for	hamadryas	4
6	assessing	method	13
7	the	effectiveness	8
8	effectiveness	method	13
9	of	effectiveness	8
10	a	peroral	11
11	peroral	of	9
12	vaccination	method	13
13	method	for	5
14	against	method	13
15	plague	against	14
16	.	Experience	0

0	Deaths	<ROOT>	-1
1	from	Deaths	0
2	rhesus	disease	4
3	haemolytic	disease	4
4	disease	from	1
5	in	disease	4
6	England	in	5
7	and	England	6
8	Wales	and	7
9	in	Deaths	0
10	1977:	accuracy	11
11	accuracy	in	9
12	of	accuracy	11
13	records	of	12
14	and	Deaths	0
15	assessment	and	14
16	of	and	14
17	anti-D	prophylaxis	18
18	prophylaxis	of	16
19	.	Deaths	0

0	The	passive	1
1	passive	transfer	2
2	transfer	<ROOT>	-1
3	of	transfer	2
4	immediate-type	airway	5
5	airway	of	3
6	responses	transfer	2
7	to	responses	6
8	nonreactive	monkeys	10
9	rhesus	monkeys	10
10	monkeys	to	7
11	by	responses	6
12	antigen	by	11
13	reactive	antigen	12
14	bronchial	reactive	13
15	lumen	mast	16
16	mast	bronchial	14
17	cells.	mast	16

0	Contribution	<ROOT>	-1
1	on	Contribution	0
2	standardisation	on	1
3	of	standardisation	2
4	the	reaction	8
5	colloidal	reaction	8
6	iron	reaction	8
7	binding	reaction	8
8	reaction	of	3
9	.	Contribution	0

0	A	assay	2
1	fluorescence	assay	2
2	assay	<ROOT>	-1
3	for	assay	2
4	4'-(9-acridinylamino)methanesulfon-m-anisidide,	for	3
5	a	agent	8
6	new	agent	8
7	antitumor	agent	8
8	agent	4'-(9-acridinylamino)methanesulfon-m-anisidide,	4
9	.	assay	2

0	Comparison	<ROOT>	-1
1	of	Comparison	0
2	mRNA	precursors	3
3	precursors	of	1
4	in	Comparison	0
5	plasmacytomas	producing	6
6	producing	in	4
7	closely	related	8
8	related	chains	10
9	kappa	chains	10
10	chains	producing	6
11	.	Comparison	0

